CYCN Cyclerion Therapeutics

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences:

  • Citi’s 15th Annual BioPharma Virtual Conference on September 9th
  • H.C. Wainwright & Co 22nd Annual Global Investment Conference on September 16th at 9:30 a.m. ET
  • Cantor Virtual Global Healthcare Conference on September 16th and a virtual Fireside Chat on September 17th at 3:20 p.m. ET
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st –23rd on September 21st at 10:50 a.m. ET

A live webcast of the H.C. Wainwright, Cantor, and Oppenheimer presentations can be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Cyclerion Therapeutics 

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Lead programs include its vascular-targeted olinciguat in Phase 2 development for sickle cell disease and IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv)

For more information about Cyclerion, please visit  and follow us on Twitter () and LinkedIn ().

Investors

Carlo Tanzi, Ph.D.

Kendall Investor Relations

EN
04/09/2020

Underlying

CYCNCyclerion Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cyclerion Therapeutics

 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof...

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board –Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIR...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and...

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression – Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept (“POC”) Study in the Second Half of 2026 – – Webcast Being Held on January 6, 2026 at 8:00 a.m. ET, Featuring Key Opinion Leader, Dr. Husseini Manji – CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cycle...

January 5, 2026 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Co...

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company – Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. today announced that it has entered into a licensing agreement with the Massachusetts Institute of Technology (“MIT”), securing the intellectual property that will serve as the cornerstone of its strategic relaunch. This agreement...

September 23, 2025 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Comp...

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strat...

December 17, 2024 1 EN
 PRESS RELEASE
Free
CYCN Cyclerion Thera...

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Regina Graul, Ph.D., Promoted to Chief Executive Officer CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluati...

August 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch